Related Experiment Video
Updated: Aug 17, 2026

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
Parecoxib. Pharmacia corp
1Professor Emeritus of Anesthesiology, State University of New York, Downstate Medical Center, New York, NY, USA.
Abstract:
Pharmacia (formerly Monsanto) is developing parecoxib, an injectable COX-2 inhibitor, for the management of post-surgical acute pain [287279], [313957]. By January 1999, the compound was in phase III trials for this indication [312280]. In October 2000, Pharmacia submitted an NDA for parecoxib sodium for the management of acute pain to the FDA. The company anticipated a 12-month review of the NDA [387654] but received a 'not approvable' letter in July 2001, indicating there were deficiencies in the filing; at this time, Pharmacia anticipated refiling before the end of 2002 [415668]. Under a license agreement with Pharmacia Corp, parecoxib (designated YM-177) is being developed in Japan by Yamanouchi [392030]. Prior to the FDA ruling, in June 2000, the company anticipated that the compound would be launched by 2001 [370466]. In March 2000, Merrill Lynch predicted that parecoxib would be filed in the third quarter of 2000 [361969], [382577]. By May 2001, the analysts revised their predictions to launch in 2002 [411811].
Related Concept Videos
Pharmaceutical Equivalents
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drug Products: Biologics, Biosimilars and Interchangeables
Pharmacokinetics: Drug–Drug Interactions
